Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alendronic acid prevents microarchitectural deterioration of trabecular bone in early postmenopausal women

Trial Profile

Alendronic acid prevents microarchitectural deterioration of trabecular bone in early postmenopausal women

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2013

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Bone resorption
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 May 2009 Planned end date changed from 1 Feb 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov record.
    • 01 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top